GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Pulmonary Tuberculosis overview

Pulmonary tuberculosis (TB) is an infectious respiratory disease caused by Mycobacterium tuberculosis, capable of spreading to other organs. The bacterium is highly contagious, transmitted through air droplets from coughs or sneezes of infected individuals. Initial infection, known as primary TB, may be asymptomatic. When symptoms manifest, they encompass breathing difficulties, chest pain, cough with mucus, blood-tinged sputum, night sweats, fatigue, fever, weight loss, and wheezing. Treatment aims to cure the infection, typically involving a combination of four medications. Administered until lab tests indicate the most effective drugs, this approach addresses active pulmonary TB and underscores the importance of adherence for successful outcomes.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

G lobalDat a, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.